pathologic myopia

path·o·log·ic my·o·pi·a

progressive myopia marked by fundus changes, posterior staphyloma, and subnormal corrected acuity.

pathologic myopia,

a type of severe, progressive nearsightedness characterized by changes in the fundus of the eye, posterior staphyloma, and deficient corrected acuity. Refractive error is greater than -8.00 diopters, and axial length is greater than 32.5 mm. Pathologic myopia increases the risk of retinal detachment by affecting the curvature of the crystalline lens.

path·o·log·ic my·o·pi·a

(path'ŏ-loj'ik mī-ō'pē-ă)
Progressive myopia marked by fundus changes, posterior staphyloma, and subnormal corrected acuity.
References in periodicals archive ?
In Japan, pathologic myopia and the associated myopic CNV is the second most common cause of blindness.
THE EUROPEAN Commission has approved Lucentis (ranibizumab) for the treatment of patients with visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia.
Laser therapy has offered limited success in treating vision-robbing ocular disorders which involve neovascularization, including age-related macular degeneration, diabetic retinopathy, pathologic myopia, and ocular tumors.
The book reviews clinical studies, details the genetics of myopia and pathologic myopia, and looks at the use of animal models in understanding the biological basis of myopia.
If the treatment effects continued over time, then the treatment could have a significant role in preventing the development of very high pathologic myopia.
Nasdaq: QLTI; Toronto) has announced that the FDA has approved Visudyne(TM) (verteporfin for injection) therapy for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to pathologic myopia (severe near-sightedness) and presumed ocular histoplasmosis.
The current market drugs include Lucentis (ranibizumab), approved for CNV associated with wet age-related macular degeneration (AMD), Visudyne (verteporfin), approved for CNV associated with wet AMD, presumed ocular histoplasmosis and pathologic myopia, and Macugen (pegaptanib), approved for CNV associated with wet AMD.
Marketing authorization applications have also been submitted in Japan for the treatment of choroidal neovascularization secondary to pathologic myopia (myopic CNV) and for the treatment of diabetic macular edema (DME).
Marketing authorization applications have been submitted in Japan for the treatment of choroidal neovascularization secondary to pathologic myopia (myopic CNV) and for the treatment of diabetic macular edema (DME).
More specifically, dedicated chapters cover corneal pathologies, age-related macular degeneration, pathologic myopia, macular hole, diabetic retinopathy, and glaucoma, among other conditions.
QLT has two marketed products: Visudyne for the treatment of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular histoplasmosis and Eligard for the palliative treatment of advanced prostate cancer.
In Japan, EYLEA has been additionally submitted for approval to regulators for the treatment of choroidal neovascularization secondary to pathologic myopia (mCNV).